Specificity of bivalent chemical degraders targeted to the BET proteins

Specificity of bivalent chemical degraders targeted to the BET proteins

Bibliographic Details
Main Authors:	A.-M. Turner, F. Potjewyd, A. Keller, L. James, D. Margolis
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020301047

Similar Items

Supertertiary structure analysis and comparison of BET proteins upon bivalent binding
by: Aihemaiti, A
Published: (2020)

Bivalent Ligands for Protein Degradation in Drug Discovery
by: Marcel Scheepstra, et al.
Published: (2019-01-01)

PP 1.24 – 00132 BET PROTACS Reveal BRD4 Disruption of the 7SK/P-TEFb Equilibrium is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells
by: A-M. Turner, et al.
Published: (2022-12-01)

A bromodomain–DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT
by: Thomas C. R. Miller, et al.
Published: (2016-12-01)

Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1
by: Meropi Bagka, et al.
Published: (2023-07-01)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family.
by: Filippakopoulos, P, et al.
Published: (2012)

Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family
by: Filippakopoulos, P, et al.
Published: (2012)

A BET family protein degrader provokes senolysis by targeting NHEJ and autophagy in senescent cells
by: Masahiro Wakita, et al.
Published: (2020-04-01)

BET Proteins as Attractive Targets for Cancer Therapeutics
by: Joanna Sarnik, et al.
Published: (2021-10-01)

Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer
by: Krishan Kumar, et al.
Published: (2023-05-01)

Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012)

Bivalent Genes Targeting of Glioma Heterogeneity and Plasticity
by: Mariam Markouli, et al.
Published: (2021-01-01)

A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease
by: Ahmed M. I. Elfiky, et al.
Published: (2022-09-01)

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats
by: Chongxiang Xiong, et al.
Published: (2021-02-01)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
by: Lennard Karsten, et al.
Published: (2022-02-01)

Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013)

Antigenic Components of Chemical Bivalent Cholera Vaccine, Methods of their Isolation and Control
by: S. A. Vorob’eva, et al.
Published: (2022-07-01)

Viral Hijacking of BET Proteins
by: Irene P. Chen, et al.
Published: (2022-10-01)

Chemical probes and inhibitors of bromodomains outside the BET family
by: Moustakim, M, et al.
Published: (2016)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
by: Zhi-Qiang Wang, et al.
Published: (2023-11-01)

Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
by: Sameer A Greenall, et al.
Published: (2012-01-01)

PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
by: Picaud, S, et al.
Published: (2013)

BET proteins are essential for the specification and maintenance of the epiblast lineage in mouse preimplantation embryos
by: Mami Tsume-Kajioka, et al.
Published: (2022-03-01)

Bivalence and determinacy
by: Rumfitt, I
Published: (2018)

Dysregulation of BET proteins in levodopa-induced dyskinesia
by: David A. Figge, et al.
Published: (2017-06-01)

Usage of nutrient Medium Based on Dry Hydrolysate of Casein in Manufacturing Bivalent Chemical Cholera Vaccine
by: N. I. Belyakova, et al.
Published: (2020-01-01)

Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases
by: Soonsil Hyun, et al.
Published: (2021-06-01)

Enhancement of Manufacturing Technology for Finished Dosage Form of Bivalent Chemical Tableted Cholera Vaccine
by: A. V. Komissarov, et al.
Published: (2016-03-01)

Interactome rewiring following pharmacological targeting of BET bromodomains
by: Lambert, J-P, et al.
Published: (2018)

BET bromodomain proteins regulate enhancer function during adipogenesis
by: Brown, Jonathan D., et al.
Published: (2018)

Histone methylation in Huntington’s disease: are bivalent promoters the critical targets?
by: Nóra Zsindely, et al.
Published: (2018-01-01)

Epicurus on bivalence and the excluded middle
by: Bown, A
Published: (2016)

The TwistDock workflow for evaluation of bivalent Smac mimetics targeting XIAP
by: Huang Q, et al.
Published: (2019-04-01)

The open future, bivalence and assertion
by: Besson, C, et al.
Published: (2014)

Biases in casino betting
by: James Sundali, et al.
Published: (2006-07-01)

Inhibition of BET bromodomain targets genetically diverse glioblastoma.
by: Cheng, Z, et al.
Published: (2013)

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
by: Cheng, Z, et al.
Published: (2013)

Bivalence and subjunctive conditionals
by: Williamson, T
Published: (1988)

BET Protein-Mediated Transcriptional Regulation in Heart Failure
by: Talha Ijaz, et al.
Published: (2021-06-01)

Delivery of a BET protein degrader via a CEACAM6-targeted antibody–drug conjugate inhibits tumour growth in pancreatic cancer models
by: Youya Nakazawa, et al.
Published: (2024-03-01)